Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer

Immune checkpoint inhibitors (ICIs) target the negative regulatory pathway of T cells and effectively reactive the anti-tumor immune function of T cells by blocking the key pathway of the immune escape mechanism of the tumor—PD-1/PD-L1, and fundamentally changing the prospect of immunotherapy for no...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yanping, Chen, Tianhong, Nie, Tian Yi, Han, Juyuan, He, Yunyan, Tang, Xingxing, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239849/
https://www.ncbi.nlm.nih.gov/pubmed/37283759
http://dx.doi.org/10.3389/fimmu.2023.1200875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239849/
https://www.ncbi.nlm.nih.gov/pubmed/37283759
http://dx.doi.org/10.3389/fimmu.2023.1200875

Ejemplares similares